Eli Lilly(NYSE: LLY) has produced a wide variety of treatments ... Lilly makes tirzepatide, which is approved for type 2 ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

Specialty pharmacies and online companies that have been selling off-brand copies of two blockbuster drugs for obesity and ...

The U.S. Food and Drug Administration re-issued a decision first made by the agency in October that a shortage of the ...

Approved in 2022 for type 2 diabetes and in 2023 for chronic weight management along with diet and exercise, tirzepatide is ...

The federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes.

Health-care companies fell amid ongoing concerns about a backlash against the industry. The SPDR Select Sector Health Care exchange-traded fund, which tracks the health-care industry group of the S&P ...

The FDA said Thursday it’s standing by its earlier decision that the shortage of tirzepatide — the active ingredient in Eli ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 480.21% and ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain ...